I think this is a difficult question. We haven’t really looked into this. We’re talking about post-neoadjuvant achievement treatments. We’re talking about treatments in patients who haven’t achieved complete or near complete pathological remission. And this is still something that needs to be debated. We have, of course, olaparib in BRCA positive tumors, which is already registered and which is a therapy of choice...
I think this is a difficult question. We haven’t really looked into this. We’re talking about post-neoadjuvant achievement treatments. We’re talking about treatments in patients who haven’t achieved complete or near complete pathological remission. And this is still something that needs to be debated. We have, of course, olaparib in BRCA positive tumors, which is already registered and which is a therapy of choice. We also have oral chemotherapies, but we don’t really know how to tackle the non-pCR achieving patients if they are not BRCA positive. I think that’s something that needs to be further elaborated, that needs to be further studied.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
